Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system

CONCLUSIONS: Our study identified new AEs that have not been reported, which provides a new guidance to deepen the comprehension of the safety of Ubrogepant.PMID:37608560 | DOI:10.1080/14740338.2023.2251390

Source: Expert Opinion on Drug Safety - August 23, 2023 Category: Drugs & Pharmacology Authors: Bing Cao Shanshan Gu Zhisen Shen Yuna Zhang Yiming Shen Hang Chen Source Type: research